Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
267.56
602.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
MDGL Price Targets Summary
Madrigal Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
MDGL
is 619.48 USD
with a low forecast of 507.02 USD and a high forecast of 945 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MDGL's stock price target?
Price Target
619.48
USD
According to Wall Street analysts, the average 1-year price target for
MDGL
is 619.48 USD
with a low forecast of 507.02 USD and a high forecast of 945 USD.
What is Madrigal Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
102%
For the last 13 years the
compound annual growth rate for
Madrigal Pharmaceuticals Inc's revenue is
28%.
The projected
CAGR
for the next 4 years is
102%.
